Global Solid Tumor Cancer Treatment Market Segments 2024, Forecast To 2033
5 Mar, 2024
The solid tumor cancer treatment market has experienced rapid growth, ascending from $200.53 billion in 2023 to $230.8 billion in 2024, with a 15.1% CAGR. Growth drivers include advancements in research, increased cancer incidence rates, and patient advocacy. The market is poised for rapid growth, reaching $382.85 billion in 2028, with a 13.5% CAGR. Trends involve immunotherapy advancements and technological innovations in treatment modalities.
Global Solid Tumor Cancer Treatment Market Key Driver
The solid tumor cancer treatment market is expanding with the increasing incidence of cancer. The American Cancer Society reported a rise in new cancer cases from 1,898,160 in 2021 to 1,918,030 in 2022. The increasing incidence of cancer is a crucial factor propelling the growth of the solid tumor cancer treatment market.
Get A Free Sample Of The Global Solid Tumor Cancer Treatment Market ReportGlobal Solid Tumor Cancer Treatment Market Segments
The solid tumor cancer treatment market covered in this report is segmented –
1) By Type: Chemotherapy, Targeted Therapy, Immunotherapy, Hormone Therapy, Surgical Procedures
2) By Application: Breast Cancer, Cervical Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Other Applications
3) By End-Users: Hospitals, Research Institutes, Homecare
By Geography: The regions covered in the anti inflammatory therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe,North America, South America, Middle East, and Africa. Among these regions.
North America was the largest region in the solid tumor cancer treatment market in 2023. The regions covered in the solid tumor cancer treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Solid Tumor Cancer Treatment Industry Players
AstraZeneca plc; Amgen Inc.; B. Braun Melsungen AG; Bristol Myers Squibb & Company; Eli Lilly & Company; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Novartis AG; Pfizer Inc.; Olympus Medical Systems; Astellas Pharma Inc.; Celgene Corporation; GlaxoSmithKline plc; Takeda Pharmaceutical Company Ltd.; Celldex Therapeutics Inc.; AbbVie Inc.; Bayer AG; Biogen Inc.; Eisai Co. Ltd.; Exelixis Inc.; Genentech Inc.; Gilead Sciences Inc.; Incyte Corporation; Ipsen Biopharmaceuticals Inc.; Janssen Biotech Inc.; Karyopharm Therapeutics Inc.; Kyowa Kirin Co. Ltd.; MedImmune LLC; Medivation Inc.; Millennium Pharmaceuticals Inc.; MorphoSys AG; Onyx Pharmaceuticals Inc.; Regeneron Pharmaceuticals Inc.; Sanofi SA; Seattle Genetics Inc.; Spectrum Pharmaceuticals Inc.; Taiho Pharmaceutical Co. Ltd.; Tesaro Inc.; Verastem Inc.; Zymeworks Inc.
Get The Full Global Solid Tumor Cancer Treatment Market Report
AIOps Solid Tumor Cancer Treatment Market Overview
Solid tumor cancer treatment refers to the treatment of an aberrant mass of tissue that does not generally contain cysts or liquid regions. Solid tumors include cancers of the brain, ovary, breast, colon, and other organs. The majority of the tumor's cells are created by cancer stem cells through division.
Solid Tumor Cancer Treatment Global Market Report 2023 provides data on the global solid tumor cancer treatment market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The solid tumor cancer treatment market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.